{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-342335","form_type":"8-K","ticker":"VERA","cik":"0001831828","company_name":"Vera Therapeutics, Inc.","filed_at":"2026-08-10T20:05:19+00:00","discovered_at":"2026-08-10T20:07:01.470364+00:00","generated_at":"2026-08-10T20:08:04.983374+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Vera Therapeutics Q2 2026 net loss $109.5M; TRUTAKNA approved and launched","bullets":["Q2 2026 net loss $109.5M ($1.52/share) vs $76.5M ($1.20) in Q2 2025; cash $499.2M at June 30, 2026.","FDA granted accelerated approval for TRUTAKNA in IgAN; first BAFF/APRIL inhibitor; U.S. launch underway.","ORIGIN 3 final efficacy analysis expected Q3 2026; sBLA submission to FDA expected Q4 2026.","Nancy Boman named Chief Regulatory Officer, succeeding William Turner upon his retirement in Q3 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-342335","json":"https://secwatch.observer/filing/0001193125-26-342335.json","markdown":"https://secwatch.observer/filing/0001193125-26-342335.md","text":"https://secwatch.observer/filing/0001193125-26-342335.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831828/000119312526342335/0001193125-26-342335-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831828/000119312526342335/vera-20260810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-10T20:08:04.983374+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}